Ethyl Pyruvate Increases Post-Ischemic Levels of Mitochondrial Energy Metabolites: A
cerebral metabolism
labeled succinate
liquid chromatography—mass spectrometry
mitochondrial dysfunction
transient ischemia
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
13 Jul 2020
13 Jul 2020
Historique:
received:
15
06
2020
revised:
09
07
2020
accepted:
10
07
2020
entrez:
17
7
2020
pubmed:
17
7
2020
medline:
17
7
2020
Statut:
epublish
Résumé
Mitochondrial dysfunction after transient cerebral ischemia can be monitored by cerebral microdialysis (CMD) using changes in the lactate and pyruvate concentrations and ratio. Other metabolites associated with mitochondrial (dys)function are, e.g., tricyclic acid (TCA) and purine metabolites. Ethyl pyruvate (EP) is a putative neuroprotectant, supposedly targeting mitochondrial energy metabolism, but its effect on cerebral energy metabolism has never been described using microdialysis. In this study we monitored the metabolic effects of EP in the endothelin-1 (ET-1) rat model using perfusion with
Identifiants
pubmed: 32668656
pii: metabo10070287
doi: 10.3390/metabo10070287
pmc: PMC7407637
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Lundbeckfonden
ID : 1759089
Références
Int J Mol Sci. 2012;13(9):11753-72
pubmed: 23109881
J Neurochem. 2012 Oct;123(1):172-81
pubmed: 22671773
Acta Neurochir Suppl. 2016;121:111-4
pubmed: 26463932
Anesthesiology. 2007 Oct;107(4):630-40
pubmed: 17893460
Acta Neurochir (Wien). 2000;142(10):1135-41; discussion 1141-2
pubmed: 11129536
Crit Care Med. 2001 Aug;29(8):1513-8
pubmed: 11505117
Acta Neurochir (Wien). 2016 Jul;158(7):1231-40
pubmed: 27188288
Acta Neurol Scand. 2014 Sep;130(3):156-63
pubmed: 24796605
Crit Care. 2016 Oct 14;20(1):277
pubmed: 27737684
Am J Physiol Endocrinol Metab. 2009 Jun;296(6):E1354-62
pubmed: 19293334
Acta Neurochir (Wien). 2017 Dec;159(12):2275-2277
pubmed: 29027015
Metabolites. 2019 Sep 27;9(10):
pubmed: 31569792
FASEB J. 2008 Nov;22(11):3938-46
pubmed: 18606862
J Neurol Neurosurg Psychiatry. 2014 Dec;85(12):1343-53
pubmed: 24847164
J Mol Med (Berl). 2009 Apr;87(4):423-33
pubmed: 19172241
Sci Rep. 2017 Feb 21;7:42891
pubmed: 28220827
Behav Brain Res. 1995 Nov;71(1-2):33-49
pubmed: 8747173
Neurosci Lett. 2009 Nov 6;465(1):55-60
pubmed: 19733210
Front Neurol. 2017 Jun 19;8:274
pubmed: 28674514
Biochem Pharmacol. 2010 Jul 15;80(2):151-9
pubmed: 20230800
Int J Biochem Cell Biol. 2010 Jun;42(6):932-7
pubmed: 20117232
Mol Neuropsychiatry. 2015 May;1(1):60-7
pubmed: 27602357
J Neurochem. 1987 Jul;49(1):227-31
pubmed: 3585332
Metabolism. 1997 Jul;46(7):801-4
pubmed: 9225835
J Cereb Blood Flow Metab. 2017 Jul;37(7):2626-2638
pubmed: 27798266
Sci Rep. 2019 Mar 6;9(1):3702
pubmed: 30842488
Br J Pharmacol. 2011 Oct;164(4):1062-78
pubmed: 21457227
Neurol Med Chir (Tokyo). 1991 Mar;31(3):129-34
pubmed: 1715045
Acta Neurochir (Wien). 1998;140(4):387-95
pubmed: 9689331
Int J Mol Sci. 2011;12(10):6469-501
pubmed: 22072900
Neuropharmacology. 2016 May;104:105-30
pubmed: 26581499
Redox Biol. 2016 Aug;8:28-42
pubmed: 26741399